Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5574210 | 0.84 | FGFR1 (0.34) | CYP17A1IDO1TDO2APP | |
| SCHEMBL3384001 | 0.70 | CYP19A1 (0.54) | — | |
| SCHEMBL5573368 | 0.68 | CHRNB2 (0.49) | HTR2A | |
| SCHEMBL1157136 | 0.67 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP1A1CYP3A4CYP2C9 | |
| SCHEMBL1180209 | 0.67 | CYP17A1 (0.41) | CYP1A2CYP3A4CYP2C19CYP17A1 | |
| SCHEMBL5570972 | 0.64 | CYP17A1 (0.45) | ADRA2CCYP17A1IDO1TDO2 | |
| SCHEMBL1181102 | 0.64 | SLC6A4 (0.43) | CYP17A1 | |
| SCHEMBL25432924 | 0.64 | CYP17A1 (0.34) | CYP17A1 | |
| SCHEMBL5048062 | 0.63 | CYP19A1 (0.48) | CYP17A1 | |
| SCHEMBL24377497 | 0.61 | CHRNB4 (0.33) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680079-B2 | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | claimed |
| US-8680079-B2 | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | disclosed |
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | CYP21A2, CYP11B1, REN | CYP1A2 46/4885CYP2D6 191/4885CYP1A1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.